Global Human Rabies Immunoglobulin (IM) market is forecast to 510 million US in 2025
Published Date: 2019/2/1
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
The classification according to the material of Human Rabies Immunoglobulin (IM) includes ERIG, HRIG, and the proportion of HRIG in 2017is about 86.7%, and the proportion is in increasing trend from 2013 to 2017.
For ERIGs, the dosage is 40 IU per kg body weight subject to a maximum of 3000 IU. For HRIGs, the dosage is 20 IU per kg body weight subject to a maximum of 1500 IU.
Human Rabies Immunoglobulin (IM) is widely used for the Category II Exposure and Category III Exposure, the most proportion of Human Rabies Immunoglobulin (IM) is used for Category III Exposure, and the proportion in 2017 is about 82.6%.
China is the largest sales place, with a sales market share nearly 61.4% in 2017, because of the population. North America enjoys 4.3% market share.
In 2017, the global Human Rabies Immunoglobulin (IM) market size was 290 million US$ and is forecast to 510 million US in 2025, growing at a CAGR of 7.6% from 2018. The objectives of this study are to define, segment, and project the size of the Human Rabies Immunoglobulin (IM) market based on company, product type, application and key regions.
Click to view the full report: https://www.qyresearch.com/index/detail/736723/global-human-rabies-immunoglobulin-im-market
Marketing: sales@qyresearchglobal.com
Media Contact: press@qyresearch.com
评论
发表评论